down arrow

Piramal Pharma

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE0DK501011
  • NSEID: PPLPHARMA
  • BSEID: 543635
INR
220.60
12.3 (5.9%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 54.01 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationHalf Yearly Results
Results Snapshot
Figures in Rs cr
Consolidate Half Yearly Results
Sep'24
Sep'23
Sep'22
Dec'21
Sep'21
Net Sales
4,192.89
3,660.23
3,202.00
4,427.74
2,888.62
Other Operating Income
0.00
0.00
0.00
0.00
0.00
Total Operating income
4,192.89
3,660.23
3,202.00
4,427.74
2,888.62
Raw Material Cost
1,046.62
949.12
845.70
1,328.46
852.47
Purchase of Finished goods
709.54
511.78
418.00
423.82
288.71
(Increase) / Decrease In Stocks
-285.32
-196.44
-25.43
-141.07
-77.36
Employee Cost
1,139.22
1,011.57
930.59
1,185.92
789.73
Power Cost
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
Other Expenses
1,036.73
986.24
843.50
1,078.91
708.96
Total Expenditure (Excl Depreciation)
3,646.79
3,262.27
3,012.36
3,876.04
2,562.51
Operating Profit (PBDIT) excl Other Income
546.10
397.96
189.64
551.70
326.11
Other Income
80.65
87.50
118.07
197.66
37.10
Operating Profit (PBDIT)
626.75
485.46
307.71
749.36
363.21
Interest
214.60
228.39
145.28
141.19
91.06
Exceptional Items
0.00
0.00
-6.96
0.00
-15.08
Gross Profit (PBDT)
412.15
257.07
155.47
593.09
257.07
Depreciation
376.77
358.12
327.85
421.02
273.87
Profit Before Tax
35.38
-101.05
-172.38
172.07
-16.80
Tax
141.09
26.01
4.99
40.14
5.46
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
Profit After Tax
-105.71
-127.06
-177.37
131.93
-22.26
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
Net Profit
-105.71
-127.06
-177.37
131.93
-22.26
Share in Profit of Associates
39.66
33.50
30.98
39.97
30.79
Minority Interest
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
-66.05
-93.56
-146.39
171.90
8.53
Equity Capital
1,323.14
1,322.95
1,193.32
1,185.91
994.60
Face Value
10.0
10.0
10.0
10.0
10.0
Reserves
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
-0.5
-0.69
-1.2
1.45
0.09
Diluted Earnings per share
-0.5
-0.75
-1.23
1.46
0.07
Operating Profit Margin (Excl OI)
13.02%
10.87%
5.92%
12.46%
11.29%
Gross Profit Margin
9.83%
7.02%
4.86%
13.39%
8.9%
PAT Margin
-1.58%
-2.56%
-4.57%
3.88%
0.3%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Half Yearly Analysis Highlights
stock-summary

Net Sales

Growth in half year ended Sep 2024 is 14.55% vs 14.31% in Sep 2023

stock-summary

Consolidate Net Profit

Growth in half year ended Sep 2024 is 29.40% vs 36.09% in Sep 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

Growth in half year ended Sep 2024 is 37.22% vs 109.85% in Sep 2023

stock-summary

Interest

Growth in half year ended Sep 2024 is -6.04% vs 57.21% in Sep 2023

stock-summary

Operating Profit Margin (Excl OI)

Growth in half year ended Sep 2024 has improved from Sep 2023

Compare Half Yearly Results Of Piramal Pharma With
Markets Mojo
Figures in Rs cr
Consolidate Half Yearly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
4,192.89
5,969.93
-1,777.04
-29.77%
Other Operating Income
0.00
0.00
0.00
Total Operating income
4,192.89
5,969.93
-1,777.04
-29.77%
Raw Material Cost
1,046.62
934.97
111.65
11.94%
Purchase of Finished goods
709.54
857.27
-147.73
-17.23%
(Increase) / Decrease In Stocks
-285.32
-104.82
-180.50
-172.20%
Employee Cost
1,139.22
1,280.21
-140.99
-11.01%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
1,036.73
1,470.50
-433.77
-29.50%
Total Expenditure (Excl Depreciation)
3,646.79
4,438.13
-791.34
-17.83%
Operating Profit (PBDIT) excl Other Income
546.10
1,531.80
-985.70
-64.35%
Other Income
80.65
210.03
-129.38
-61.60%
Operating Profit (PBDIT)
626.75
1,741.83
-1,115.08
-64.02%
Interest
214.60
18.01
196.59
1,091.56%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
412.15
1,723.82
-1,311.67
-76.09%
Depreciation
376.77
213.36
163.41
76.59%
Profit Before Tax
35.38
1,510.46
-1,475.08
-97.66%
Tax
141.09
314.99
-173.90
-55.21%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
-105.71
1,195.47
-1,301.18
-108.84%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
-105.71
1,195.47
-1,301.18
-108.84%
Share in Profit of Associates
39.66
6.48
33.18
512.04%
Minority Interest
0.00
-11.99
11.99
100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
-66.05
1,189.96
-1,256.01
-105.55%
Equity Capital
1,323.14
40.06
1,283.08
3,202.90%
Face Value
10.00
1.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
-0.50
29.70
-30.20
-101.68%
Diluted Earnings per share
-0.50
29.65
-30.15
-101.69%
Operating Profit Margin (Excl OI)
13.02%
25.66%
0.00
-12.64%
Gross Profit Margin
9.83%
28.88%
0.00
-19.05%
PAT Margin
-1.58%
20.13%
0.00
-21.71%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Half Yearly - Net Sales
Net Sales 4,192.89 Cr
in Sep 2024

Figures in Rs Cr
stock-summary

Growth in half year ended Sep 2024 is 14.55% vs 14.31% in Sep 2023

Half Yearly - Consolidate Net Profit
Consolidate Net Profit -66.05 Cr
in Sep 2024

Figures in Rs Cr
stock-summary

Growth in half year ended Sep 2024 is 29.40% vs 36.09% in Sep 2023

Half Yearly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 546.10 Cr
in Sep 2024

Figures in Rs Cr
stock-summary

Growth in half year ended Sep 2024 is 37.22% vs 109.85% in Sep 2023

Half Yearly - Interest
Interest 214.60 Cr
in Sep 2024

Figures in Rs Cr
stock-summary

Growth in half year ended Sep 2024 is -6.04% vs 57.21% in Sep 2023

Half Yearly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 13.02%
in Sep 2024

Figures in Rs %
stock-summary

Growth in half year ended Sep 2024 has improved from Sep 2023